[go: up one dir, main page]

MX2009004134A - Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble. - Google Patents

Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.

Info

Publication number
MX2009004134A
MX2009004134A MX2009004134A MX2009004134A MX2009004134A MX 2009004134 A MX2009004134 A MX 2009004134A MX 2009004134 A MX2009004134 A MX 2009004134A MX 2009004134 A MX2009004134 A MX 2009004134A MX 2009004134 A MX2009004134 A MX 2009004134A
Authority
MX
Mexico
Prior art keywords
treatment
demyelinating disorders
demyelinating
disorders
inhibitors
Prior art date
Application number
MX2009004134A
Other languages
English (en)
Inventor
Jenny P-Y Ting
Jeffrey Browning
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MX2009004134A publication Critical patent/MX2009004134A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Métodos para tratar un trastorno de desmielinización utilizando inhibidores de la trayectoria de linfotoxina.
MX2009004134A 2006-10-20 2007-10-18 Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble. MX2009004134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86234306P 2006-10-20 2006-10-20
PCT/US2007/081761 WO2008049053A2 (en) 2006-10-20 2007-10-18 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor

Publications (1)

Publication Number Publication Date
MX2009004134A true MX2009004134A (es) 2009-08-12

Family

ID=39314832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004134A MX2009004134A (es) 2006-10-20 2007-10-18 Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.

Country Status (14)

Country Link
US (2) US8067375B2 (es)
EP (2) EP2073833A2 (es)
JP (3) JP2010506955A (es)
KR (2) KR20090083958A (es)
CN (2) CN101600450A (es)
AU (1) AU2007311052B2 (es)
BR (1) BRPI0718283A2 (es)
CA (1) CA2666934A1 (es)
EA (1) EA200900581A1 (es)
IL (1) IL198196A0 (es)
MX (1) MX2009004134A (es)
NZ (1) NZ576424A (es)
SG (2) SG178002A1 (es)
WO (1) WO2008049053A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112325A2 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN102770020B (zh) * 2009-12-17 2015-07-15 赛诺菲 在髓鞘碱性蛋白启动子的控制下表达荧光素酶(mbp-luci)的动物模型和所述模型用于生物发光体内成像的用途
WO2014127258A2 (en) * 2013-02-14 2014-08-21 Cornell University Methods to protect against and treat multiple sclerosis
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP6382499B2 (ja) 2013-10-31 2018-08-29 株式会社Ｎｔｔドコモ 無線基地局、ユーザ端末及び無線通信方法
CN104922670A (zh) * 2015-05-06 2015-09-23 武汉奥斯梅得生物医药有限公司 融合免疫蛋白在制备治疗多发性硬化症药物中的应用
CN107213456B (zh) * 2017-05-25 2020-08-21 苏州华测生物技术有限公司 淋巴毒素衍生物的新用途
JP2022513449A (ja) 2018-12-12 2022-02-08 オートバーン セラピューティクス，インク． 新規な甲状腺模倣物
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN112305226A (zh) * 2019-07-31 2021-02-02 首都医科大学附属北京天坛医院 抗人gfap自身抗体检测试剂盒及制备方法
EP4065098A4 (en) 2019-11-29 2023-12-27 Autobahn Therapeutics, Inc. NOVEL THYROMIMETICS

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4758549A (en) * 1983-12-13 1988-07-19 Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US4959457A (en) * 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
CA2001756A1 (en) 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1991000347A1 (en) 1989-07-04 1991-01-10 Novo Nordisk A/S Method of producing proteins with fviii activity and/or fviii derivatives
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
JPH06501456A (ja) * 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
NZ240718A (en) 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
EP0672143B1 (en) 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5726039A (en) * 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
PT809510E (pt) 1995-01-26 2004-09-30 Biogen Inc Complexos de linfotoxina-alfa/beta e anticorpos receptores de anti-linfotoxina-beta como agentes anti-tumor
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
GB9514518D0 (en) 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
TR199802238T2 (xx) 1996-05-08 1999-02-22 F. Hoffmann-La Roche Ag Astımın TNFR-Ig ile tedavisi.
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
ATE331531T1 (de) 1996-10-25 2006-07-15 Biogen Idec Inc Lösliche lymphotoxin-beta rezeptoren, anti- lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
EP0948543A1 (en) 1996-12-12 1999-10-13 Genentech, Inc. Hvem polypeptides and uses thereof
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
IL137489A0 (en) 1998-01-30 2001-07-24 Univ New York Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
WO1999053059A1 (en) 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
PL195264B1 (pl) * 1998-10-09 2007-08-31 Biogen Idec Inc Zastosowania limfotoksyny-beta lub czynnika blokującego receptor limfotoksyny-beta, zastosowanie polipeptydu z domeną wiążacą ligand ludzkiego LT-beta-R oraz zastosowania czynnika blokującego receptor limfotoksyny-beta i/lub szlak sygnalizacji HVEM
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1326897A2 (en) * 2000-10-13 2003-07-16 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
EP1583503A4 (en) * 2002-12-20 2006-08-09 Biogen Idec Inc POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF
CN1753692A (zh) * 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 淋巴毒素β受体药剂与化疗剂的联合用药
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
JP2009539999A (ja) 2006-06-15 2009-11-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 第２の薬剤との組み合わせにおいてリンホトキシンベータ受容体結合分子を使用する複合療法
WO2008112325A2 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders

Also Published As

Publication number Publication date
KR20090071652A (ko) 2009-07-01
CN101600450A (zh) 2009-12-09
US20100099608A1 (en) 2010-04-22
WO2008049053A2 (en) 2008-04-24
AU2007311052A1 (en) 2008-04-24
CA2666934A1 (en) 2008-04-24
EP2311481A3 (en) 2013-10-16
JP2010506955A (ja) 2010-03-04
KR20090083958A (ko) 2009-08-04
EP2073833A2 (en) 2009-07-01
WO2008049053A3 (en) 2008-10-23
BRPI0718283A2 (pt) 2013-11-12
US8067375B2 (en) 2011-11-29
AU2007311052B2 (en) 2014-01-16
JP2013227340A (ja) 2013-11-07
US20120244153A1 (en) 2012-09-27
IL198196A0 (en) 2011-08-01
JP2009242419A (ja) 2009-10-22
CN101653599A (zh) 2010-02-24
EA200900581A1 (ru) 2009-08-28
EP2311481A2 (en) 2011-04-20
SG154441A1 (en) 2009-08-28
NZ576424A (en) 2012-09-28
SG178002A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
MX2009004134A (es) Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.
ZA200807715B (en) 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders
ZA200900734B (en) Combination treatment for metabolic disorders
TN2011000239A1 (en) Hsp90 inhibitor combinations
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2007087468A3 (en) Adiponectin for treatment of various disorders
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL195203A0 (en) Compounds for the treatment of metabolic disorders
GB2467710B (en) Methods for treating social disorders
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX339116B (es) Tratamiento de esclerosis tuberosa.
WO2008011487A3 (en) L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
ZA201001262B (en) Interval therapy for the treatment of tinnitus
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
MY150600A (en) Use of opioid antagonists for treating urinary retention
ZA200805645B (en) Compounds for the treatment of metabolic disorders
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
GB0617734D0 (en) Method of treating peripheral nerve disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL195392A0 (en) Compounds for the treatment of metabolic disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
IL202001A0 (en) Axomadol for treating pain from arthritis
WO2008011485A3 (en) Methods for treating chronic pain
ZA200904478B (en) Novel therapeutic use for treating leukaemia

Legal Events

Date Code Title Description
FG Grant or registration